Bifogade filer
The Board of Directors of Prostatype Genomics AB determines record date for reverse split of shares
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
2024-10-25
The Board of Directors of Prostatype Genomics AB (“Prostatype”), based on the authorization granted by the extraordinary general meeting held on October 22, 2024, has set the record date for the reverse split of the company’s shares to November 1, 2024.
On October 22, 2024, the extraordinary general meeting in Prostatype resolved to carry out a reverse split of shares, meaning that one thousand (1,000) existing shares will be consolidated into one (1) new share. The Board has now, in accordance with the general meeting’s authorization, determined the record date for the reverse split of shares to be November 1, 2024. Shareholders whose holdings are not evenly divisible by one thousand (1,000) on the record date will receive, free of charge, the number of shares necessary for the holdings to be evenly divisible by one thousand (1,000). The receipt of shares as described above and the reverse split of shares will be handled by Euroclear Sweden AB without any action required by the company’s shareholders.
The last day for trading in the company’s shares prior to the reverse split of shares is October 30, 2024, and the first day for trading in the company’s shares after the reverse split of shares is October 31, 2024. The actual value of an individual shareholder’s holdings is not affected by the reverse split of shares. Thus, the shareholder’s percentage of the total number of shares in the company and the value of the individual shareholding remain unchanged. The reverse split of shares is primarily being carried out to achieve a more reasonable trading price for the company’s shares.
As a result of the reverse split of shares, Prostatype will change its ISIN code. Starting from October 31, 2024, the shares in the company will be traded under the new ISIN code SE0023261532.
Last day of share trading with the current ISIN code: October 30, 2024 First day of trading with the new ISIN code: October 31, 2024 Record date for the reverse split of shares: November 1, 2024 Shares with the new ISIN code are registered in shareholders’ securities accounts: November 4, 2024
Key dates for the reverse split of shares [1]
| Extraordinary General Meeting resolves on the reverse split of shares | 22 October 2024 |
| The Board decides on the record date for the reverse split of shares | 25 October 2024 |
| Last day of trading with the current ISIN code | 30 October 2024 |
| First day of trading with the new ISIN code | 31 October 2024 |
| Record date for the reverse split of shares | 1 November 2024 |
| Shares with the new ISIN code are registered in shareholders’ securities accounts | 4 November 2024 |
About Us
About Prostatype Genomics AB
Prostatype® is a gene test available to patients and treating urologists as a supplementary decision-making tool regarding the question of treatment or non-treatment of prostate cancer. The test is developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.
Contacts
For further information, contact:
Fredrik Rickman (formerly Persson), CEO of Prostatype Genomics AB,
Phone: +46 73 049 77 01
E-mail: fredrik.persson@prostatypegenomics.com
Certified Advisor
Carnegie Investment Bank AB (publ), +46 (0)73 856 42 65, certifiedadviser@carnegie.se
[1] Dates referring to future events are preliminary and may therefore be subject to change.